Electronic patient diaries in clinical research

Size: px
Start display at page:

Download "Electronic patient diaries in clinical research"

Transcription

1 Topics Electronic diaries in Clinical Trials Electronic diaries versus Paper Electronic patient diaries in clinical research Case Study: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry Isabella Montagna Annamaria Muraro Electronic diaries compliance with regulations Good Clinical Data Management Practices Case study: Forward, CHIESI Farmaceutici The EXACT-PRO questionnaire on BlackBerry Electronic data flow Electronic diaries improvement in study Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions 2

2 Electronic diaries Electronic diaries Subjects diaries are essential in clinical trials that assess occurrence and intensity of symptoms, effects of medication, perceived quality of life. Scientific research has consistently demonstrated that paper diaries make difficult for subjects to comply with the protocol. Otherwise electronic diaries ensure undeniable advantages. By capturing data directly from patients at home, they solve problems often experienced by using paper diaries. What electronic diaries do (and paper diaries don t) Record date and time for each entry automatically Prevent to skip mandatory information Allow to enter only formatted responses Remind automatically to complete Transfer data directly to a central database Make real-time data available to all More pharmaceutical companies worldwide replace paper diaries with electronic ones. 3 4

3 Electronic diaries vs paper Electronic diaries vs paper Electronic diaries Pros Reliable, real time data Reduced missing data Reduced data entry errors High diaries compliance and possibility to monitor it Real time access to study and patient data Integration with clinical databases Cons Training required Familiarity with technology More startup resources needed Paper diaries Pros Established medium Fewer startup resources No training required Easy to produce Cons No reliable date/time stamping (retrospective data entry) Poor quality of data (incomplete, unreadable information, inappropriate responses) Lack of compliance 5 6

4 Electronic diaries compliance with regulations FDA draft Guidance for industry: Electronic Source documentation in Clinical Investigations (January 2011). EMA Expectations from Electronic Source Data and Data Transcribed To Electronic Data Collection Tools in Clinical Trials (September 2010). FDA Guidance for industry: Patient Reported Outcome measures: Use in in Medical Product Development to support Labeling Claims (December 2009). CDISC Leveraging the CDISC standard to facilitate the use of electronic source data within clinical trials (November 2006). US 21 CFR Part 11 Electronic records, electronic signatures (1997) Electronic Diaries - Good Clinical Data Management Practices Electronic diaries collect Patient Reported Outcome to quantify symptoms, disability, emotional states, responses to treatment, Questionnaires are often developed to measure PRO and to quantify the results by established algorithms. Best Practices for epro Use standard, validated questionnaires. Provide detailed instructions to subjects for completion of the electronic diary and conduct appropriate training. Ensure electronic systems are proper validated in compliance with US 21 CFR Part 11. Ensure all processes are in place to assure compliance with regulatory requirements regardind protection and ownership of electronic data. Ensure appropriare level of network security and infrastructure. 7 8

5 Case Study: Forward, CHIESI Farmaceutici Case Study: Forward, CHIESI Farmaceutici Forward is a Clinical Study sponsored by Chiesi Farmaceutici aimed at demonstrating that Foster, a drug registered to cure a severe respiratory pathology called asthma, can be also used to effectively cure another respiratory disease called Chronic Obstructive Pulmonary Disease (COPD). More than 1000 patients involved from 18 countries and treated for 48 weeks. The Clinical Study must satisfy all regulatory authorities and legislation requirements, reaching an effective symptoms control that can be obtained only with a day-by-day report from patients about their health status and frequent visits to the medical centres. To comply with protocol requirements, Chiesi Farmaceutici adopted the solution of electronic diaries. Blackberries were identified as the best technological platform to host the EXACT-PRO questionnaire. 9 10

6 The EXACT-PRO questionnaire The EXACT-PRO questionnaire The EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) is a patient-reported outcome (PRO) measure designed to standardize the method for evaluating the frequency, severity, and duration of acute exacerbations of COPD and chronic bronchitis (AECB) in international studies and clinical trials. The EXACT is a 14-item daily diary to be completed by the patient on the device each evening before bedtime, taking less than 3 minutes to complete. Chiesi customized EXACT-PRO with 4 study specific additional questions. 14 questions Total score - 0 to 100 (higher scores = more severe health status) Domain scores - Scoring 0 to 100 (higher scores = more severe symptoms) - Breathlessness (5 Items) - Cough and Sputum (2 Items) - Chest Symptoms (3 Items) 4 custom questions to record information on rescue medication and study treatment intake

7 EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry The electronic diary on BlackBerry was given to each patient for recording: Daily symptoms and patient status Use of recue medication Compliance of study medication intake. The patients were instructed on how to use the device. Mean patients age: 64 years To facilitate patients in approaching technology, the following measurements were adopted: the clinical study application is the ONLY application to which the users have access only one question per page is displayed. To achieve compliance with the protocol, the following settings were applied: each question must be answered and edited by patients patients can edit today s diary only notifications remind patients to fill in the questionnaire. BlackBerry is one of the most user-friendly device

8 EXACT-PRO on BlackBerry EXACT-PRO on BlackBerry To comply with privacy requirements: patients remain anonymous to Chiesi who only gets data about questionnaire tracking BlackBerry PIN communications are encrypted no data are stored on the device but information are immediately transmitted to the central database and synchronized in a secure Web portal. No need for telephone line (only mobile signal required). Patients health is always controlled by notifications automatically sent to patients and investigators. Notifications to the patients Global (automatically scheduled and delivered) Individual (in case of symptoms worsening) Please remember to call your doctor if your symptoms worsen. Notifications to the investigators Variation in patient s symptoms will trigger an alert that will be sent by or by text

9 Electronic diaries data flow Electronic diaries compliance Subjects Diary Database Diary Web Portal BlackBerries compliance during treatment period EXACT-PRO ALERT Investigator ALERT CHIESI Clinical database Compliance = total days recorded in the BB / total days expected * 100 Mean compliance = 88.64% 17 18

10 Detection of ECOPD with EXACT-PRO and BlackBerry Detection of ECOPD with EXACT-PRO and BlackBerry Electronic diaries but not only +12 pt Threshold Exacerbations of COPD are estimated from persistent increase in daily symptoms that require treatment with systemic steroids, antibiotics and/or hospitalization/er visit. CHIESI Farmaceutici employs electronic diaries on BlackBerry to automatically detect possible ECOPD. A baseline score is set in the device to identify the patient s stable condition. Baseline score = value calculated during the 14 days run-in period when patients are treated with their maintenance therapy. Baseline 1 event as per the EXACT-PRO detection definition Any variation in score of at least 12 points for two consecutives day is considered as significant worsening of the patient s status

11 Detection of ECOPD with EXACT-PRO and BlackBerry Conclusions Electronic diaries improvement in studies More precise data as they are collected daily. Real-time data available both to investigators and sponsor. Daily monitoring of patients health. Daily monitoring of patients compliance in BlackBerry usage and in study medication intake. A - The EXACT-PRO detection threshold matches the diagnosed ECOPD. B - Patient s condition worsens according to symptoms recorded in the BB but no subsequent treatment until further worsening triggering treatment. C - No clear worsening recorded in the BB but patient receives treatment for ECOPD. Corrective actions immediately in place to correct lack of compliance: additional training to patient BlackBerry replacement in case of device malfunction. Savings in questionnaires collections (automatic data transfer to the clinical database) and analysis Savings in the visits with doctors

Your Go-to COPD Guide

Your Go-to COPD Guide Your Go-to COPD Guide Learning how to live with chronic obstructive pulmonary disease (COPD) Inside, you ll learn: COPD facts COPD symptoms and triggers How to talk with your doctor Different treatment

More information

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital Mahidol University Journal of Pharmaceutical Sciences 008; 35(14): 81. Original Article Outcome of Drug Counseling of Outpatients in Chronic Obstructive Pulmonary Disease Clinic at Thawangpha Hospital

More information

Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis What is Idiopathic Pulmonary Fibrosis? Idiopathic pulmonary fibrosis (IPF) is a condition that causes persistent and progressive scarring of the tiny air sacs (alveoli) in

More information

PLAN OF ACTION FOR. Physician Name Signature License Date

PLAN OF ACTION FOR. Physician Name Signature License Date PLAN OF ACTION FOR Patient s copy (patient s name) I Feel Well Lignes I feel short directrices of breath: I cough up sputum daily. No Yes, colour: I cough regularly. No Yes I Feel Worse I have changes

More information

Agenda. ARITHMOS Presents: Introduction to epro. EDC and epro integration General Overview. epro and ecrf Integration: a case study

Agenda. ARITHMOS Presents: Introduction to epro. EDC and epro integration General Overview. epro and ecrf Integration: a case study Agenda ARITHMOS Presents: epro and ecrf Integration: a case study Introduction to epro EDC and epro integration General Overview From epro to ipro: Technology trend in Pharma epro EDC integration: A case

More information

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION

1 ALPHA-1. What is Alpha-1? A family history... of lung disease? of liver disease? FOUNDATION What is Alpha-1? A family history... of lung disease? of liver disease? What you need to know about Alpha-1 Antitrypsin Deficiency 1 ALPHA-1 FOUNDATION What is Alpha-1? Alpha-1 Antitrypsin Deficiency (Alpha-1)

More information

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care

Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Management of exacerbations in chronic obstructive pulmonary disease in Primary Care Acute exacerbations of chronic obstructive pulmonary disease (COPD) are associated with significant morbidity and mortality.

More information

Prevention of Acute COPD exacerbations

Prevention of Acute COPD exacerbations December 3, 2015 Prevention of Acute COPD exacerbations George Pyrgos MD 1 Disclosures No funding received for this presentation I have previously conducted clinical trials with Boehringer Ingelheim. Principal

More information

COPD - Education for Patients and Carers Integrated Care Pathway

COPD - Education for Patients and Carers Integrated Care Pathway Patient NHS COPD - Education for Patients and Carers Integrated Care Pathway Date ICP completed:. Is the patient following another Integrated Care Pathway[s].. / If yes, record which other Integrated Care

More information

Documenting & Coding. Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC

Documenting & Coding. Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC Documenting & Coding Chronic Obstructive Pulmonary Disease (COPD) Presented by: David S. Brigner, MLA, CPC Sr. Provider Training & Development Consultant Professional Profile David Brigner currently performs

More information

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD) Patients with COPD take a wide variety of medicines to manage their symptoms these include: Inhaled Short Acting Bronchodilators

More information

Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective

Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective Using Patient Reported Outcome as Primary or Key Secondary Endpoints-A Regulatory Perspective Shiling Ruan FDA/CDRH/OSB/DBS Advamed-FDA Statistics Workshop, Gaithersburg, MD Apr 29-30, 2009 1 Acknowledgment

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical

More information

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family

1 ALPHA-1. Am I an Alpha-1 Carrier? FOUNDATION FOUNDATION. Learn how being an Alpha-1 carrier can affect you and your family Am I an Alpha-1 Carrier? 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

More information

1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease

1 ALPHA-1. The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) FOUNDATION FOUNDATION. A patient s guide to Alpha-1 liver disease The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people

More information

Role of eclinical Systems in FDA Regulated Studies. Jonathan S. Helfgott

Role of eclinical Systems in FDA Regulated Studies. Jonathan S. Helfgott Role of eclinical Systems in FDA Regulated Studies Presented by: Jonathan S. Helfgott Operations Research Analyst Office of Scientific Investigations Disclaimer The contents of this presentation are my

More information

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medical Policy An independent licensee of the Blue Cross Blue Shield Association Afrezza Page 1 of 6 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Afrezza (human insulin) Prime Therapeutics will review Prior Authorization requests Prior Authorization

More information

Guideline for Industry

Guideline for Industry Guideline for Industry The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Longterm Treatment of Non-Life- Threatening Conditions ICH-E1A March 1995 GUIDELINE FOR INDUSTRY

More information

The Value of A Qualified Outcome Measure Janet Woodcock, M.D.

The Value of A Qualified Outcome Measure Janet Woodcock, M.D. The Value of A Qualified Outcome Measure Janet Woodcock, M.D. The Critical Path Institute (CPI) Multiple Sclerosis Outcome Assessments Consortium (MSAOC) 1 April 2013 White Oak 1 Overview of Workshop Create

More information

Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials

Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials Session 8: Bring Your Own Device (BYOD) - Application in Clinical Trials FIFTH ANNUAL PATIENT-REPORTED OUTCOME (PRO) CONSORTIUM WORKSHOP April 29-30, 2014 Silver Spring, MD Co-sponsored by Disclaimer The

More information

COPD and Asthma Differential Diagnosis

COPD and Asthma Differential Diagnosis COPD and Asthma Differential Diagnosis Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death in America. Learning Objectives Use tools to effectively diagnose chronic obstructive

More information

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011

Objectives COPD. Chronic Obstructive Pulmonary Disease (COPD) 4/19/2011 Objectives Discuss assessment findings and treatment for: Chronic Obstructive Pulmonary Disease Bronchitis Emphysema Asthma Anaphylaxis Other respiratory issues Provide some definitions Chronic Obstructive

More information

Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims

Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims U.S. Department of Health and Human Services Food and Drug Administration Center for

More information

Mobile Medical Application Development: FDA Regulation

Mobile Medical Application Development: FDA Regulation Mobile Medical Application Development: FDA Regulation Mobile Medical Applications: Current Environment Currently over 100,000 mobile health related applications are available for download; there is an

More information

What Lies Ahead? Trends to Watch: Health Care Product Development in North America

What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? Trends to Watch: Health Care Product Development in North America What Lies Ahead? for 2015 DIA has released its third annual What Lies Ahead? report, providing experts insights into the

More information

James F. Kravec, M.D., F.A.C.P

James F. Kravec, M.D., F.A.C.P James F. Kravec, M.D., F.A.C.P Chairman, Department of Internal Medicine, St. Elizabeth Health Center Chair, General Internal Medicine, Northeast Ohio Medical University Associate Medical Director, Hospice

More information

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION

The Liver and Alpha-1. Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION The Liver and Alpha-1 Antitrypsin Deficiency (Alpha-1) 1 ALPHA-1 FOUNDATION What Is Alpha-1 Antitrypsin Deficiency? Alpha-1 is a condition that may result in serious lung disease in adults and/or liver

More information

Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care

Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care Hospital to Physician Office to Home: A Respiratory Led Program Across the Continuum of Care Charley P. Starnes, RRT, RCP Clinical Respiratory Specialist- COPD Education Important Milestones July 2011-

More information

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International

Data Management and Good Clinical Practice Patrick Murphy, Research Informatics, Family Health International Data Management and Good Clinical Practice Patrick Murphy,, Family Health International 1 What is GCP? Good Clinical Practice is an international ethical and scientific quality standard for designing,

More information

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators]

PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] PCOM Letterhead [Substitute same from participating institution and, of course, change Department, PI, and Co-Investigators] Department of Neuroscience, Physiology and Pharmacology 215-871-6880 PATIENT

More information

Monitoring Clinical Trials with a SAS Risk-Based Approach

Monitoring Clinical Trials with a SAS Risk-Based Approach Paper DH05 Monitoring Clinical Trials with a SAS Risk-Based Approach Laurie Rose, SAS, Cary, NC USA ABSTRACT With global regulatory encouragement, the life sciences industry is gaining momentum to embrace

More information

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version

INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE. Current Step 4 version INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE THE EXTENT OF POPULATION EXPOSURE TO ASSESS CLINICAL

More information

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL

Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL Marilyn Borkgren-Okonek, APN, CCNS, RN, MS Suburban Lung Associates, S.C. Elk Grove Village, IL www.goldcopd.com GLOBAL INITIATIVE FOR CHRONIC OBSTRUCTIVE LUNG DISEASE GLOBAL STRATEGY FOR DIAGNOSIS, MANAGEMENT

More information

Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011)

Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011) Quit & Get Fit! Frequently Asked Questions For Personal Trainers (November 2011) What is Quit & Get Fit? Quit & Get Fit is an initiative of the Ontario Lung Association, made possible through funding from

More information

Longitudinal Modeling of Lung Function in Respiratory Drug Development

Longitudinal Modeling of Lung Function in Respiratory Drug Development Longitudinal Modeling of Lung Function in Respiratory Drug Development Fredrik Öhrn, PhD Senior Clinical Pharmacometrician Quantitative Clinical Pharmacology AstraZeneca R&D Mölndal, Sweden Outline A brief

More information

SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS

SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS E-Resource December, 2013 SLEEP DISTURBANCE AND PSYCHIATRIC DISORDERS Between 10-18% of adults in the general population and up to 50% of adults in the primary care setting have difficulty sleeping. Sleep

More information

ASK A DOC. Clinical Trial Update May 28, 2014. Welcome!

ASK A DOC. Clinical Trial Update May 28, 2014. Welcome! ASK A DOC Clinical Trial Update May 28, 2014 Welcome! ASK A DOC CLINICAL TRIAL UPDATE Dr. Gregory Cosgrove PFF Chief Medical Officer Dr. Kevin Flaherty Chairman Steering Committee PFF CCN and PFF Registry

More information

EUROPEAN LUNG FOUNDATION

EUROPEAN LUNG FOUNDATION PULMONARY REHABILITATION understanding the professional guidelines This guide includes information on what the European Respiratory Society and the American Thoracic Society have said about pulmonary rehabilitation.

More information

EU PAS Register Guide

EU PAS Register Guide 29 March 2016 EMA/613603/2012 (currently ENCePP E-Register of Studies) The EU PAS Register is temporarily hosted on the ENCePP website www.encepp.eu 1. Introduction... 2 2. ENCePP E-Register as a temporary

More information

COPD PROTOCOL CELLO. Leiden

COPD PROTOCOL CELLO. Leiden COPD PROTOCOL CELLO Leiden May 2011 1 Introduction This protocol includes an explanation of the clinical picture, diagnosis, objectives and medication of COPD. The Cello way of working can be viewed on

More information

The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process

The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process Wissenschaftliche Prüfungsarbeit zur Erlangung des Titels Master of Drug Regulatory

More information

An Overview of Asthma - Diagnosis and Treatment

An Overview of Asthma - Diagnosis and Treatment An Overview of Asthma - Diagnosis and Treatment Asthma is a common chronic disorder of the airways that is complex and characterized by variable and recurring symptoms, airflow obstruction, bronchial hyperresponsiveness,

More information

Guidance for Industry

Guidance for Industry Guidance for Industry Electronic Source Data in Clinical Investigations U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Center for

More information

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol

University of Hawai i Human Studies Program. Guidelines for Developing a Clinical Research Protocol University of Hawai i Human Studies Program Guidelines for Developing a Clinical Research Protocol Following are guidelines for writing a clinical research protocol for submission to the University of

More information

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am

Exploratory data: COPD and blood eosinophils. David Price: 9.23-9.35am Exploratory data: COPD and blood eosinophils David Price: 9.23-9.35am Blood Eosinophilia in COPD The reliability and utility of blood eosinophils as a marker of disease burden, healthcare resource utilisation

More information

Bronchodilators in COPD

Bronchodilators in COPD TSANZSRS Gold Coast 2015 Can average outcomes in COPD clinical trials guide treatment strategies? Long live the FEV1? Christine McDonald Dept of Respiratory and Sleep Medicine Austin Health Institute for

More information

Better Breathing with COPD

Better Breathing with COPD Better Breathing with COPD People with Chronic Obstructive Pulmonary Disease (COPD) often benefit from learning different breathing techniques. Pursed Lip Breathing Pursed Lip Breathing (PLB) can be very

More information

epro Integration with Oracle Remote Data Capture

epro Integration with Oracle Remote Data Capture epro Integration with Oracle Remote Data Capture BIAS Congress 27-28 May 2010 Rome (IT) Davide Di Giovine, CROS NT Senior DM & CSV Manager [email protected] AGENDA Changes in handling of clinical

More information

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) European Medicines Agency Evaluation of Medicines for Human Use London, 19 July 2007 Doc. Ref: EMEA/27170/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON COMPASSIONATE USE OF MEDICINAL

More information

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations

Measure Information Form (MIF) #275, adapted for quality measurement in Medicare Accountable Care Organizations ACO #9 Prevention Quality Indicator (PQI): Ambulatory Sensitive Conditions Admissions for Chronic Obstructive Pulmonary Disease (COPD) or Asthma in Older Adults Data Source Measure Information Form (MIF)

More information

COPD It Can Take Your Breath Away www.patientedu.org

COPD It Can Take Your Breath Away www.patientedu.org written by Harvard Medical School COPD It Can Take Your Breath Away www.patientedu.org What Is COPD? COPD stands for chronic obstructive pulmonary disease. There are 2 major diseases included in COPD:

More information

Sponsor Novartis Pharmaceuticals

Sponsor Novartis Pharmaceuticals Clinical Trial Results Database Page 1 Sponsor Novartis Pharmaceuticals Generic Drug Name Indacaterol Therapeutic Area of Trial Chronic Obstructive Pulmonary Disease (COPD) Indication studied: COPD Study

More information

Inhaler Technique Check

Inhaler Technique Check Protocol October 2015 Version 1.3 Table of Contents Service Information... 2 Service objective... 2 Clinical service overview... 2 Documentation... 3 Staff Roles... 3 Facilities to support the program...

More information

Respiratory Clinical Trial Services. the difference is clear. Your respiratory clinical trials partner

Respiratory Clinical Trial Services. the difference is clear. Your respiratory clinical trials partner Respiratory Clinical Trial Services the difference is clear Your respiratory clinical trials partner Our heritage We at Vitalograph are proud of our 50 year heritage as a world leading respiratory specialist.

More information

Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification

Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification Department of Telecommunication Engineering Hijjawi Faculty for Engineering Technology Yarmouk University Wireless Remote Monitoring System for ASTHMA Attack Detection and Classification Prepared by Orobh

More information

Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business

Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business Coventry Health Care of Florida, Inc. Coventry Health Plan of Florida, Inc. Coventry Health and Life Insurance Company Commercial Lines of Business Quality Management Program 2012 Overview Quality Improvement

More information

3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients

3/11/15. COPD Disease Management Tackling the Transition. Objectives. Describe the multidisciplinary approach to inpatient care for COPD patients Faculty Disclosures COPD Disease Management Tackling the Transition Dr. Cappelluti has no actual or potential conflicts of interest associated with this presentation. Jane Reardon has no actual or potential

More information

NEW RESPIRATORY HEALTH PROGRAM

NEW RESPIRATORY HEALTH PROGRAM NEW RESPIRATORY HEALTH PROGRAM Introducing the Medavie Blue Cross Managing Chronic Disease Program Medavie Blue Cross is proud to announce our innovative new approach to managing chronic disease- the first

More information

TravelCare Medical Questionnaire Instruction Sheet for Agents

TravelCare Medical Questionnaire Instruction Sheet for Agents TravelCare Medical Questionnaire Instruction Sheet for Agents Helpful Reminders: We want your client to be comfortable when completing the Medical Questionnaire. It is important that you remind your client

More information

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014

ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 ST. MICHAEL S HOSPITAL Guidelines for Reporting Serious Adverse Events / Unanticipated Problems to the SMH Research Ethics Board (REB) July 09, 2014 1. Introduction The St. Michael s Hospital (SMH) REB

More information

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma

Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis, and asthma Chapter 31 Drugs Used to Treat Lower Respiratory Disease Learning Objectives Describe the physiology of respirations Compare the physiologic responses of the respiratory system to emphysema, chronic bronchitis,

More information

Quality Management in Clinical Trials

Quality Management in Clinical Trials CLINICAL CASE STUDY SERIES Quality Management in Clinical Trials Clinical trials are conducted to collect the data necessary to provide information for academia, industry, and regulators to make decisions

More information

CMS National Coverage Policy

CMS National Coverage Policy LCD ID Number L32764 LCD Title Pulmonary Rehabilitation (PR) Programs Contractor s Determination Number L32764 AMA CPT/ADA CDT Copyright Statement CPT only copyright 2002-2011 American Medical Association.

More information

Using Social Media in Research: Regulatory and IRB Considerations

Using Social Media in Research: Regulatory and IRB Considerations Using Social Media in Research: Regulatory and IRB Considerations Webinar Housekeeping Questions & Answers Feel free to submit questions at any point during the webinar using the chat box on your webinar

More information

Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014)

Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014) Medicare Pulmonary Rehabilitation (PR) Benefit Frequently Asked Questions June 2010 (Latest Updates: December 18, 2013 and February 12, 2014) Coverage Criteria Q. CMS has stated that only patients with

More information

Guidance for Industry

Guidance for Industry Guidance for Industry IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer U.S. Department of Health and Human Services Food and Drug Administration Center

More information

ASTHMA IN INFANTS AND YOUNG CHILDREN

ASTHMA IN INFANTS AND YOUNG CHILDREN ASTHMA IN INFANTS AND YOUNG CHILDREN What is Asthma? Asthma is a chronic inflammatory disease of the airways. Symptoms of asthma are variable. That means that they can be mild to severe, intermittent to

More information

Licensed Healthcare Providers Guidelines for Telemedicine Using the MyDocNow Platform

Licensed Healthcare Providers Guidelines for Telemedicine Using the MyDocNow Platform Contents 1. Scope of These Guidelines... 2 2. What is Telemedicine?... 2 3. Introduction... 3 4. What Are the Benefits of Telemedicine?... 3 5. Frequently Asked Questions Physician Care and Treatment...

More information

BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION

BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION BEACON HEALTH STRATEGIES, LLC TELEHEALTH PROGRAM SPECIFICATION Providers contracted for the telehealth service will be expected to comply with all requirements of the performance specifications. Additionally,

More information

ROLE OF THE RESEARCH COORDINATOR

ROLE OF THE RESEARCH COORDINATOR Clinical and Translational Science Institute / CTSI at the University of California, San Francisco Welcome to Online Training for Clinical Research Coordinators ROLE OF THE RESEARCH COORDINATOR Data Collection

More information

Medicare Part A. Pulmonary Rehab Program Services Web-Based Training February 25, 2010 - Q & As

Medicare Part A. Pulmonary Rehab Program Services Web-Based Training February 25, 2010 - Q & As Pulmonary Rehab Program Services Web-Based Training February 25, 2010 - Q & As The following are the question and answers from the Pulmonary Rehabilitation Program Services web-based training which was

More information

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2):

GENERAL INFORMATION. Adverse Event (AE) Definition (ICH GUIDELINES E6 FOR GCP 1.2): Make copies of the blank SAE report form as needed. Retain originals with confirmation of all information faxed to DMID Pharmacovigilance Group Clinical Research Operations and Management Support (CROMS

More information

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS

COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT OF POST-MARKETING SURVEILLANCE STUDIES OF VETERINARY MEDICINAL PRODUCTS The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/CVMP/044/99-FINAL COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS GUIDELINE FOR THE CONDUCT

More information

Efficient Asset Tracking: From Manual to Automated

Efficient Asset Tracking: From Manual to Automated White Paper Efficient Asset Tracking: From Manual to Automated Asset Tracking Overview: Asset Tracking Basics: The Fixed Asset Register Managing a Fixed Asset Register Asset Identification Technologies

More information

Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs

Telehealth Solutions Enhance Health Outcomes and Reduce Healthcare Costs Text for a pull out can go heretext for a pull out can go heretext for a pull out can go Text for a pull out can go here Text for a pull out can go here Telehealth Solutions Enhance Health Outcomes and

More information

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575

J of Evolution of Med and Dent Sci/ eissn- 2278-4802, pissn- 2278-4748/ Vol. 3/ Issue 65/Nov 27, 2014 Page 13575 EFFECT OF BREATHING EXERCISES ON BIOPHYSIOLOGICAL PARAMETERS AND QUALITY OF LIFE OF PATIENTS WITH COPD AT A TERTIARY CARE CENTRE Sudin Koshy 1, Rugma Pillai S 2 HOW TO CITE THIS ARTICLE: Sudin Koshy, Rugma

More information

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to

Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to Welcome to the training on the TransCelerate approach to Risk-Based Monitoring. This course will take you through five modules of information to introduce you to the concepts behind risk-based monitoring,

More information

EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software DECISION SUMMARY

EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software DECISION SUMMARY A. DEN Number: DEN140016 EVALUATION OF AUTOMATIC CLASS III DESIGNATION FOR STUDIO on the Cloud Data Management Software B. Purpose for Submission: DECISION SUMMARY De novo request for adjunct data management

More information

Principal Investigator and Sub Investigator Responsibilities

Principal Investigator and Sub Investigator Responsibilities Principal Investigator and Sub Investigator Responsibilities I. Purpose To define the roles and responsibilities of Principal Investigators conducting research at GRU. II. Definition The term Principal

More information

Supplement to the Guidance for Electronic Data Capture in Clinical Trials

Supplement to the Guidance for Electronic Data Capture in Clinical Trials Supplement to the Guidance for Electronic Data Capture in Clinical Trials January 10, 2012 Drug Evaluation Committee, Japan Pharmaceutical Manufacturers Association Note: The original language of this

More information

Frequently Asked Questions about Crab Asthma

Frequently Asked Questions about Crab Asthma Frequently Asked Questions about Crab Asthma 1. Occupational asthma to snow crab: What is it? Asthma is a condition that results in breathing difficulties. These breathing difficulties occur when the breathing

More information

Chronic Obstructive Pulmonary Disease (COPD) Programme

Chronic Obstructive Pulmonary Disease (COPD) Programme Integrated Care Pathway Chronic Obstructive Pulmonary Disease (COPD) Programme Patient Handbook Contents Preface... 1 What is COPD?... 3 What causes COPD?... 4 - Smoking... 4 - Air pollution... 4 - The

More information

Development of Case Report Forms

Development of Case Report Forms Development of Case Report Forms Introduction to the Principles and Practice of Clinical Research February 12, 2013 Diane St. Germain, RN, MS Nurse Consultant Division of Cancer Prevention National Cancer

More information

Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification

Disease Management Identifications and Stratification Health Risk Assessment Level 1: Level 2: Level 3: Stratification Disease Management UnitedHealthcare Disease Management (DM) programs are part of our innovative Care Management Program. Our Disease Management (DM) program is guided by the principles of the UnitedHealthcare

More information

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure

Subject: No. Page PROTOCOL AND CASE REPORT FORM DEVELOPMENT AND REVIEW Standard Operating Procedure 703 1 of 11 POLICY The Beaumont Research Coordinating Center (BRCC) will provide advice to clinical trial investigators on protocol development, content and format. Upon request, the BRCC will review a

More information

COPD. Information brochure for chronic obstructive pulmonary disease.

COPD. Information brochure for chronic obstructive pulmonary disease. COPD Information brochure for chronic obstructive pulmonary disease. CONTENTS What does COPD mean?...04 What are the symptoms of COPD?...06 What causes COPD?...09 Treating COPD...10 Valve therapy in COPD...12

More information